Synovis Life Technologies, Inc. Signs Agreement With Caldera Medical
"We are pleased to partner with Caldera, a company that shares our commitment to providing products that improve the quality of patients' lives," said Karen Gilles Larson, chief executive officer of Synovis Life Technologies. "By partnering with such a focused organization, this relationship will expand the footprint of our Veritas technology in these markets, allowing our own Synovis sales force to focus on the bariatric market and other synergistic call points where we see excellent opportunities."
"We are excited about the prospect of working with Synovis and offering its Veritas technology," said Byron L. Merade, chief executive officer of Caldera Medical. "This addition broadens our portfolio of superior products and allows us to offer surgeons another treatment modality to best serve their patients' individual needs."
Veritas is an implantable biomaterial which Caldera will sell as Hydrix XM for the surgical treatment of pelvic organ prolapse and stress urinary incontinence (SUI), both common conditions in post-menopausal women. The product is a collagen matrix biomaterial derived from bovine pericardium, a material known to have excellent characteristics for surgical applications. Veritas, or Hydrix XM as it will be branded, is not resorbed by the body, but rather provides a scaffold upon which the body's own tissue can grow into, effectively "remodeling" the implant into the host.
About Caldera Medical
Caldera Medical is dedicated to bringing innovative medical devices to the marketplace. Caldera focuses exclusively on differentiated, high-impact products across the gynecology, urology and urogynecology specialties.
Caldera Medical is a privately held company located in Agoura Hills, California. For more information, visit Caldera's Web site at http://www.calderamedical.com .
About Synovis Life Technologies
Synovis Life Technologies, Inc., based in St. Paul, Minnesota, is a diversified medical device company engaged in developing, manufacturing and bringing to market medical devices for the surgical and interventional treatment of disease. For additional information on Synovis Life Technologies and its businesses, visit the company's Web site at http://www.synovislife.com .
Forward-looking statements contained in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The statements can be identified by words such as "should," "could," "may," "will," "expect," "believe," "anticipate," "estimate," "continue," or other similar expressions. Certain important factors that could cause results to differ materially from those anticipated by the forward-looking statements made herein include the timing of product introductions, outcomes of clinical and market trials as well as regulatory submissions, the number of certain surgical procedures performed, the level of orders from contract manufacturing customers, and the effectiveness of the company's transition to a domestic direct sales force in its surgical business, as well as the other factors found in the company's Annual Report on Form 10-K for the year ended October 31, 2005.
Source: Synovis Life Technologies, Inc.